Under the agreement, Heinrich Heine University Düsseldorf will use OmniComm’s TrialMaster EDC technology to develop and conduct clinical trials at multiple sites.

As a key division of the Faculty of Medicine at Heinrich Heine University, KKS supports clinical research trials undertaken at the institution.

In addition to building new clinical trials in TrialMaster, the university will migrate a number of ongoing trials to the TrialMaster platform. The agreement provides KKS with the opportunity to enhance the efficiency and effectiveness of its clinical trials. KKS selected OmniComm because of TrialMaster’s inherent flexibility and broad capabilities to support clinical trials across all phases of clinical development.

“We are honored to be partnering with KKS in supporting such a prestigious University as they strive to improve the quality of clinical trials and continue to develop further competence in the academic sector,” said Stephen Johnson, president and CEO of OmniComm.

Source: Company Press Release